Posters

Outcomes in eyes with poor initial vision due to neovascular age-related macular degeneration.

Poster Details

First Author: R.Manrique Lipa SPAIN

Co Author(s):    M. Asencio Duran   J. Abelairas Gomez   C. Hijar Ordovas                       

Abstract Details



Purpose:

To describe visual outcomes in patients with neovascular age-related macular degeneration (AMD) treated with anti-VEGF intravitreal injections and baseline poor visual acuity.

Setting:

Ophthalmology Department. Hospital Santa Barbara, Soria, Spain.

Methods:

Retrospective, observational study. Fifty six naïve patients older than 50 years old with exudative AMD treated with anti-VEGF injections with a follow up at least one year and initial best corrected visual acuity (BCVA) worse than 0,1 (decimal) or equivalent > +1,0 LogMAR were included. A complete medical and ophthalmology data were recorded, which included: age, gender, baseline and final visual acuity, changes in BCVA (improvement +0,3 LogMAR, worsen -0,3 LogMAR, and no changes), central macular thickness and optical coherence tomography (OCT) characteristics.

Results:

Time of follow-up was 26 months (12-67 months). Mean baseline BCVA was +1,6 LogMAR and final BCVA was +1,5 LogMAR, difference no significant (p=0,07). In 19 eyes (33,9%) baseline BCVA was < +1,3 LogMAR, in which the mean final BCVA was +1,2 LogMAR ; in 37 eyes (66,1%) baseline BCVA were > +1,3 LogMAR, in which the mean final BCVA was +1,6 LogMAR, difference significant (p=0,001). Likewise, of cases with baseline BCVA < +1,3 LogMAR, 13 cases (63,2%) maintained o improved final BCVA. On the contrary, of cases with baseline BCVA > +1,3 LogMAR, 29 eyes (79,8%) maintained or worsened final BCVA. Mean central retinal thickness decreased from 359um ± 126um to 298um ± 122um (p=0,002). Of all cases, improvement (+0,3 LogMAR) was found in 13 patients (20%), worsening (-0,3 LogMAR) in 7 patients (10,3%) and no changes in BCVA were found in 36 patients (53%). In multivariate analysis, final BCVA was predicted by baseline BCVA and inversely to baseline central macular thickness (thicker macula, better vision).

Conclusions:

Patients with neovascular AMD and low visual acuity (<0.1 decimal) benefit from anti-VEGF intravitreal injections. More than half of patients maintain baseline BCVA and one fifth improve baseline visual acuity. Patients with a baseline BCVA < +1,3LogMAR improve significantly compared to > +1,3 LogMAR during follow up. Final BCVA could be predicted by baseline BCVA and baseline central macular thickness.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy